Oxamflatin

目录号: GC17472纯度: >98.00%同义词: Metacept-3
Inhibitor of histone deacetylases

Oxamflatin
Cas No.: 151720-43-3
规格价格库存数量操作
1mg¥540.00现货
1
5mg¥1,620.00现货
1
10mg¥2,520.00现货
1

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

Oxamflatin is a potent histone deacetylase inhibitor with IC50 value of 15.7 nM [1].

Histone deacetylases (HADC) are a series of enzymes that remove acetyl groups from an ε-N-acetyl lysine amino acid on a histone and make the histones to wrap the DNA more tightly, which prevent transcription.

Oxamflatin is a potent histone deacetylase inhibitor and a novel antitumor compound. In mouse and human tumor cell lines, such as P388, Lewis, Lu-99, HT-29 and HeLa cells, Oxamflatin exhibited antiproliferative activity. In HeLa cells, Oxamflatin changed cell morphology, and significantly reduced the number of the cells in S phase and increased the number of cells in G0/G1 phase [1]. In the HIV-1 latently infected Jurkat T cell line, Oxam?atin increased the acetylation level of histone H3 and histone H4 at the nucleosome 1(nuc-1) site of the HIV-1 LTR and activated HIV-1 gene expression by 2-17 fold, suggesting that Oxam?atin has potential as drug candidates as antilatency therapies [2]. In OVCAR-5 and SKOV-3 ovarian cancer cell lines, oxamflatin decreased cell viability and significantly inhibited DNA synthesis and cell proliferation. Also, oxamflatin reduced the expression of c-Myc, CDK4 and E2F1, and the phosphorylation level of Rb protein, but upregulated p21 [3].

In mice transplanted with B16 murine melanoma, Oxamflatin (20 mg/kg) injected intraperitoneally six times on day 1, 3, 5, 7, 9 and 11 significantly increased the days of survival [1].

References:
[1].Kim YB, Lee KH, Sugita K, et al.  Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene. 1999 Apr 15;18(15):2461-70.
[2].Yin H, Zhang Y, Zhou X, et al.  Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. Mol Biol Rep. 2011 Nov;38(8):5071-8.
[3].Wang YL, Liui HL, Fu RG, et al.  HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines. Curr Mol Med. 2016;16(3):232-42.

实验参考方法 Experimental Reference Method

Cell experiment:

Cells grown in DMEM supplemented with 10% fetal bovine serum are challenged with serial two fold dilutions of oxamflatin on day 1 after the cells are seeded, and incubated for 2 days for the suspension cell cultures and for 3 days for the adherent cell cultures. Inhibition of the cell growth by oxamflatin is determined by staining with MTT as described previously[1].

Animal experiment:

Mice: Oxamflatin is injected intraperitoneally into BDF1 mice on day 1, 3, 5, 7, 9 and 11 and after the intraperitoneal inoculation of single cell suspension of the B16 melanoma cells. The survival days of the animals are recorded and the percent of increased life span (ILS%) is calculated[1].

References:

[1]. Kim YB, et al. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene. 1999 Apr 15;18(15):2461-70.
[2]. Wang YL, et al. HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines. Curr Mol Med. 2016;16(3):232-42.
[3]. Faghihloo E, et al. The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line. Cancer Gene Ther. 2016 Nov;23(11):396-399.

产品文档 Product Documents

Purity:>98.00%

化学性质Chemical Properties

CAS 号
151720-43-3
同义词
Metacept-3
化学名
(1Z,2E)-N-hydroxy-5-(3-(phenylsulfonamido)phenyl)pent-2-en-4-ynimidic acid
SMILES
OC(/C([H])=C([H])/C#CC1=CC(NS(C2=CC=CC=C2)(=O)=O)=CC=C1)=N\O
分子式
C17H14N2O4S
分子量
342.37 g/mol
溶解性
DMF: 10 mg/ml,DMF:PBS (pH 7) (1:10): 0.1 mg/ml,DMSO: 5 mg/ml,DMSO:PBS (pH 7.2) (1:10): 0.1 mg/ml,Ethanol: 0.5 mg/ml
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备 RT,或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol